BioSig Technologies Issues November 2019 Shareholder Letter
November 14 2019 - 7:52AM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company developing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that the Company has issued its November
2019 Shareholder Letter.
Shareholder Letter highlights include:
- Commercialization plans that include the installation of PURE
EP™ Systems at up to 9 centers throughout the U.S. in the first
half of 2020
- Updates on Texas Cardiac Arrhythmia Institute’s (TCAI)
evaluation of clinical cases
- Further PURE EP™ System installations are scheduled to begin at
the University of Pennsylvania in Philadelphia and at Mayo Clinic
in Jacksonville before year end
- Clinical trial with the PURE EP™ System to commence in November
2019
- The Company’s subsidiary, NeuroClear Technologies, Inc., raised
$3.7 million in initial funding
- New licensing agreement with Mayo Clinic and the opening of a
new corporate office in Rochester, MN to support our Mayo
collaboration
- Presented first clinical observations at Venice Arrhythmias
2019, a distinguished industry event held every two years in Italy,
and at the 14th Annual International Symposium on Ventricular
Arrhythmias: Pathophysiology & Therapy
- Additions of key personnel and a new Board member and updates
to our intellectual property portfolio.
To view the Company’s November 2019 Shareholder Letter, please
visit our website: https://ir.biosig.com. About
BioSig Technologies BioSig Technologies is a medical
technology company developing a proprietary biomedical signal
processing platform designed to improve the electrophysiology (EP)
marketplace (www.biosig.com). Led by a proven management team and a
veteran Board of Directors, BioSig Technologies is preparing to
commercialize its PURE EP(tm) System. The technology has been
developed to address an unmet need in a large and growing
market.
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory. The system is indicated for use under the supervision
of licensed healthcare practitioners who are responsible for
interpreting the data. This novel cardiac signal acquisition and
display system is engineered to assist electrophysiologists in
clinical decision-making during electrophysiology procedures in
patients with abnormal heart rates and rhythms. BioSig’s ultimate
goal is to deliver technology to improve upon catheter ablation
treatments for the prevalent and potentially deadly arrhythmias,
Atrial Fibrillation and Ventricular Tachycardia. BioSig has
partnered with Minnetronix on technology development and received
FDA 510(k) clearance for the PURE EP(tm) System in August 2018.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) our inability to manufacture our products and
product candidates on a commercial scale on our own, or in
collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the
size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Contact:
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x119
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024